Measurements of birth defect prevalence: Which is most useful as a comparator group for pharmaceutical pregnancy registries?

Angela Scheuerle, Vani X. Vannappagari, Mary K. Miller

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Pharmaceutical pregnancy registries document birth defects and other complications reported in pregnancies exposed to specific medications or diseases. A baseline estimate of birth defect prevalence is necessary for comparison. To identify potential teratogenic signals, the pregnancy registry must have a comparator that most closely matches the exposed population and data collection methodology, which are characteristics that vary among the multiplicity of birth defect surveillance systems. The system that yields the most accurate prevalence data may be different from that most closely matching the pregnancy registry methods. State public health programs have highly accurate and precise statistics, but their populations are broader than those of a pharmaceutical pregnancy registry. Large collaborative databases may have a more useful covered population, but there are secondary problems related to data precision. Health care databases enroll large numbers of patients and have good information about exposures and health problems, but the data can be difficult to access and lack useful detail. Exposure-related databases are closer in population definition and collection methods, though the presence of different diseases and exposures can be problematic. Internal comparators are likely to be most useful in formal statistical analysis, but added cost and management burden and may require significantly increased registry enrollment. There is no ideal comparator, and this must be taken into account when planning a single-exposure or single-disease pregnancy registry.

Original languageEnglish (US)
Pages (from-to)611-620
Number of pages10
JournalBirth Defects Research Part A - Clinical and Molecular Teratology
Volume85
Issue number7
DOIs
StatePublished - Jul 2009

Fingerprint

Registries
Pregnancy
Pharmaceutical Preparations
Databases
Population
Population Characteristics
Public Health
Delivery of Health Care
Costs and Cost Analysis
Health

Keywords

  • Birth defect
  • Birth defect prevalence
  • Pregnancy registry

ASJC Scopus subject areas

  • Developmental Biology
  • Pediatrics, Perinatology, and Child Health
  • Embryology

Cite this

Measurements of birth defect prevalence : Which is most useful as a comparator group for pharmaceutical pregnancy registries? / Scheuerle, Angela; Vannappagari, Vani X.; Miller, Mary K.

In: Birth Defects Research Part A - Clinical and Molecular Teratology, Vol. 85, No. 7, 07.2009, p. 611-620.

Research output: Contribution to journalArticle

@article{db32cbd251b34d82b6176bb67b8b53cf,
title = "Measurements of birth defect prevalence: Which is most useful as a comparator group for pharmaceutical pregnancy registries?",
abstract = "Pharmaceutical pregnancy registries document birth defects and other complications reported in pregnancies exposed to specific medications or diseases. A baseline estimate of birth defect prevalence is necessary for comparison. To identify potential teratogenic signals, the pregnancy registry must have a comparator that most closely matches the exposed population and data collection methodology, which are characteristics that vary among the multiplicity of birth defect surveillance systems. The system that yields the most accurate prevalence data may be different from that most closely matching the pregnancy registry methods. State public health programs have highly accurate and precise statistics, but their populations are broader than those of a pharmaceutical pregnancy registry. Large collaborative databases may have a more useful covered population, but there are secondary problems related to data precision. Health care databases enroll large numbers of patients and have good information about exposures and health problems, but the data can be difficult to access and lack useful detail. Exposure-related databases are closer in population definition and collection methods, though the presence of different diseases and exposures can be problematic. Internal comparators are likely to be most useful in formal statistical analysis, but added cost and management burden and may require significantly increased registry enrollment. There is no ideal comparator, and this must be taken into account when planning a single-exposure or single-disease pregnancy registry.",
keywords = "Birth defect, Birth defect prevalence, Pregnancy registry",
author = "Angela Scheuerle and Vannappagari, {Vani X.} and Miller, {Mary K.}",
year = "2009",
month = "7",
doi = "10.1002/bdra.20572",
language = "English (US)",
volume = "85",
pages = "611--620",
journal = "Teratology",
issn = "1542-0752",
publisher = "Wiley-Liss Inc.",
number = "7",

}

TY - JOUR

T1 - Measurements of birth defect prevalence

T2 - Which is most useful as a comparator group for pharmaceutical pregnancy registries?

AU - Scheuerle, Angela

AU - Vannappagari, Vani X.

AU - Miller, Mary K.

PY - 2009/7

Y1 - 2009/7

N2 - Pharmaceutical pregnancy registries document birth defects and other complications reported in pregnancies exposed to specific medications or diseases. A baseline estimate of birth defect prevalence is necessary for comparison. To identify potential teratogenic signals, the pregnancy registry must have a comparator that most closely matches the exposed population and data collection methodology, which are characteristics that vary among the multiplicity of birth defect surveillance systems. The system that yields the most accurate prevalence data may be different from that most closely matching the pregnancy registry methods. State public health programs have highly accurate and precise statistics, but their populations are broader than those of a pharmaceutical pregnancy registry. Large collaborative databases may have a more useful covered population, but there are secondary problems related to data precision. Health care databases enroll large numbers of patients and have good information about exposures and health problems, but the data can be difficult to access and lack useful detail. Exposure-related databases are closer in population definition and collection methods, though the presence of different diseases and exposures can be problematic. Internal comparators are likely to be most useful in formal statistical analysis, but added cost and management burden and may require significantly increased registry enrollment. There is no ideal comparator, and this must be taken into account when planning a single-exposure or single-disease pregnancy registry.

AB - Pharmaceutical pregnancy registries document birth defects and other complications reported in pregnancies exposed to specific medications or diseases. A baseline estimate of birth defect prevalence is necessary for comparison. To identify potential teratogenic signals, the pregnancy registry must have a comparator that most closely matches the exposed population and data collection methodology, which are characteristics that vary among the multiplicity of birth defect surveillance systems. The system that yields the most accurate prevalence data may be different from that most closely matching the pregnancy registry methods. State public health programs have highly accurate and precise statistics, but their populations are broader than those of a pharmaceutical pregnancy registry. Large collaborative databases may have a more useful covered population, but there are secondary problems related to data precision. Health care databases enroll large numbers of patients and have good information about exposures and health problems, but the data can be difficult to access and lack useful detail. Exposure-related databases are closer in population definition and collection methods, though the presence of different diseases and exposures can be problematic. Internal comparators are likely to be most useful in formal statistical analysis, but added cost and management burden and may require significantly increased registry enrollment. There is no ideal comparator, and this must be taken into account when planning a single-exposure or single-disease pregnancy registry.

KW - Birth defect

KW - Birth defect prevalence

KW - Pregnancy registry

UR - http://www.scopus.com/inward/record.url?scp=67651180665&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67651180665&partnerID=8YFLogxK

U2 - 10.1002/bdra.20572

DO - 10.1002/bdra.20572

M3 - Article

C2 - 19215016

AN - SCOPUS:67651180665

VL - 85

SP - 611

EP - 620

JO - Teratology

JF - Teratology

SN - 1542-0752

IS - 7

ER -